Found: 36
Select item for more details and to access through your institution.
Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2944, doi. 10.1111/dom.15191
- By:
- Publication type:
- Article
Cost‐effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 3030, doi. 10.1111/dom.15201
- By:
- Publication type:
- Article
Safety of sodium‐glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta‐analysis of randomized controlled trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2963, doi. 10.1111/dom.15193
- By:
- Publication type:
- Article
Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the GARFIELD‐AF registry.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 3040, doi. 10.1111/dom.15202
- By:
- Publication type:
- Article
Back Cover.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. C4, doi. 10.1111/dom.15286
- By:
- Publication type:
- Article
Inside Front Cover.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. C2, doi. 10.1111/dom.15285
- By:
- Publication type:
- Article
Front Cover.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. C1, doi. 10.1111/dom.15284
- By:
- Publication type:
- Article
Management of the 'wicked' combination of heart failure and chronic kidney disease in the patient with diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2795, doi. 10.1111/dom.15181
- By:
- Publication type:
- Article
Effects of sodium‐glucose co‐transporter‐2 inhibitors by background cardiovascular medications: A systematic review and meta‐analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 3020, doi. 10.1111/dom.15200
- By:
- Publication type:
- Article
Variants within the LPL gene confer susceptility to diabetic kidney disease and rapid decline in kidney function in Chinese patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 3012, doi. 10.1111/dom.15199
- By:
- Publication type:
- Article
Incidence of atrial and ventricular arrhythmias in obese patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2999, doi. 10.1111/dom.15198
- By:
- Publication type:
- Article
The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2989, doi. 10.1111/dom.15197
- By:
- Publication type:
- Article
Contemporary trends in the utilization of second‐line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2980, doi. 10.1111/dom.15196
- By:
- Publication type:
- Article
Therapeutic carbohydrate restriction and sodium‐glucose transporter 2 inhibitors in chronic kidney disease: A potentially powerful combination.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2791, doi. 10.1111/dom.15195
- By:
- Publication type:
- Article
Prescription of guideline‐directed medical therapies in patients with diabetes and chronic kidney disease from the CURE‐CKD Registry, 2019‐2020.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2970, doi. 10.1111/dom.15194
- By:
- Publication type:
- Article
Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24‐week, randomized, double‐blind, placebo‐controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2954, doi. 10.1111/dom.15192
- By:
- Publication type:
- Article
Association of socioeconomic deprivation with sleep health in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2937, doi. 10.1111/dom.15190
- By:
- Publication type:
- Article
Combining polygenic risk scores and human leukocyte antigen variants for personalized risk assessment of type 1 diabetes in the Taiwanese population.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2928, doi. 10.1111/dom.15187
- By:
- Publication type:
- Article
Urinary α1 microglobulin level is useful for selecting sodium‐glucose transporter 2 inhibitor or metformin for visceral fat reduction in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 3071, doi. 10.1111/dom.15188
- By:
- Publication type:
- Article
Development and validation of a real‐world model to predict 1‐year Level 3 (severe) hypoglycaemia risk in adults with diabetes (the iNPHORM study, United States).
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2910, doi. 10.1111/dom.15186
- By:
- Publication type:
- Article
The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2888, doi. 10.1111/dom.15183
- By:
- Publication type:
- Article
All‐cause mortality and cardiovascular outcomes with sodium‐glucose Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2897, doi. 10.1111/dom.15185
- By:
- Publication type:
- Article
An update on the incidence of type 1 diabetes during the COVID‐19 pandemic years.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 3068, doi. 10.1111/dom.15182
- By:
- Publication type:
- Article
Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open‐label, crossover trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 3064, doi. 10.1111/dom.15180
- By:
- Publication type:
- Article
A prediction model on incident chronic kidney disease among individuals with type 2 diabetes in the United States.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2862, doi. 10.1111/dom.15177
- By:
- Publication type:
- Article
Diabetes remission in drug‐naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2878, doi. 10.1111/dom.15179
- By:
- Publication type:
- Article
Evaluating the clinical effectiveness and safety of insulin glargine 300 U/mL in individuals with type 2 diabetes uncontrolled on basal insulin: A real‐world evidence study from Saudi Arabia (EVOLUTION).
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2869, doi. 10.1111/dom.15178
- By:
- Publication type:
- Article
Sumatriptan, a serotonin 5HT<sub>1B</sub> receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 3059, doi. 10.1111/dom.15176
- By:
- Publication type:
- Article
Nutritional strategies for correcting low glucose values in patients with postbariatric hypoglycaemia: A randomized controlled three‐arm crossover trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2853, doi. 10.1111/dom.15175
- By:
- Publication type:
- Article
Neighbourhood‐level social deprivation and the risk of recurrent heart failure hospitalizations in type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2846, doi. 10.1111/dom.15174
- By:
- Publication type:
- Article
Trajectories of fasting glucose and glycated haemoglobin in obese and non‐obese incident diabetes: Results from two large cohort studies.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2835, doi. 10.1111/dom.15173
- By:
- Publication type:
- Article
Risk of hospitalization with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real‐world data.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 3054, doi. 10.1111/dom.15172
- By:
- Publication type:
- Article
Respiratory effort during sleep and the rate of prevalent type 2 diabetes in obstructive sleep apnoea.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2815, doi. 10.1111/dom.15169
- By:
- Publication type:
- Article
Severe hypoglycaemia in adults presenting to a hospital emergency department: Clinical characteristics, comorbidities, and mortality outcomes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2824, doi. 10.1111/dom.15170
- By:
- Publication type:
- Article
Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2805, doi. 10.1111/dom.15168
- By:
- Publication type:
- Article
Diabetes, Obesity and Metabolism.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2789, doi. 10.1111/dom.14757
- Publication type:
- Article